Bommireddy Ramireddy, Stone Shannon, Bhatnagar Noopur, Kumari Pratima, Munoz Luis E, Oh Judy, Kim Ki-Hye, Berry Jameson T L, Jacobsen Kristen M, Jaafar Lahcen, Naing Swe-Htet, Blackerby Allison N, Gaag Tori Van der, Wright Chloe N, Lai Lilin, Pack Christopher D, Ramachandiran Sampath, Suthar Mehul S, Kang Sang-Moo, Kumar Mukesh, Reddy Shaker J C, Selvaraj Periasamy
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.
Vaccines (Basel). 2022 Jun 14;10(6):944. doi: 10.3390/vaccines10060944.
Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since millions of people are exposed to influenza virus and SARS-CoV-2, it is of great interest to develop a two-in-one vaccine that will be able to protect against infection of both viruses. We have developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 RBD fused to GM-CSF as an adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid vaccine induced a strong antibody response and protected mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice. These results suggest that a hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections.
有几种方法已研制出针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的有效疫苗。由于数以百万计的人接触流感病毒和SARS-CoV-2，因此开发一种能够预防这两种病毒感染的二合一疫苗具有重大意义。我们利用通过蛋白质转移掺入的流感病毒样颗粒（VLP），开发了一种针对SARS-CoV-2和流感病毒的混合疫苗，其中糖基磷脂酰肌醇（GPI）锚定的SARS-CoV-2受体结合域（RBD）与GM-CSF融合作为佐剂。GPI-RBD-GM-CSF融合蛋白在CHO-S细胞中表达、纯化，并掺入流感VLP中以开发混合疫苗。我们的结果表明，该混合疫苗诱导了强烈的抗体反应，并保护小鼠免受流感病毒和小鼠适应的SARS-CoV-2攻击，与未接种的小鼠相比，接种疫苗的小鼠肺部病毒滴度显著降低。这些结果表明，混合疫苗策略是开发预防甲型流感和SARS-CoV-2感染的多价疫苗的一种有前景的方法。
